Abstract
Introduction
A missense variant (rs373863828, p.(Arg457Gln)) in CREBRF (encoding CREB3 regulatory factor) has been associated with body mass index (BMI) in the Samoan population residing in Samoa and American Samoa [1] . The minor allele (c.1370A p.(457Gln)) associated with a 1.36kg/m 2 higher BMI
(or approximately 4kg in body weight, assuming a height of 1.7m) per copy, with an ~1.3 fold greater risk of obesity [1, 2] . In a small sample of individuals from the Kingdom of Tonga (n=171) the minor allele associated with a greater BMI of 3.1kg/m 2 [3] . The high minor allele frequency (MAF) of the rs373863828 missense variant among Samoans in Samoa and American Samoa (MAF = 0.26) and in the Kingdom of Tonga (MAF = 0.15) [1, 3] , compared to an exceedingly rare frequency in other populations in the Genome Aggregation Database (gnomad.broadinstitute.org; MAF=5.3x10 -5 in East
Asian, 3.3x10 -5 in South Asian, 4.0x10 -5 in European, absent in ~12K African individuals) [4] , supports the hypothesis that rs373863828 is an important risk factor for obesity unique to the Samoan and Tongan populations and possibly other Polynesian populations.
Unlike FTO-IRX3 and many other obesity risk variants in other populations, the BMI-increasing allele of rs373863828 associates with lower odds of type 2 diabetes (T2D) (OR = 0.59-0.74 after adjustment for BMI) [1] . This is contrary to the established observational association between T2D and increased BMI. Recently, however, genetic variants have also been associated with higher BMI and lower risk of T2D, hypertension and coronary artery disease in European populations [5] [6] [7] . For example, in the UK Biobank, a genetic score of eleven such alleles, including in the IRS1 and PPARG loci, was associated with higher BMI (+0.12kg/m 2 ) and higher body fat percentage (+0.30%) [8] . However, for a given BMI, individuals carrying these alleles were at reduced odds for T2D (OR=0.84), hypertension (OR=0.94) and heart disease (OR=0.92) [8] . These observations suggest that some molecular mechanisms that lead to higher BMI and higher body fat percentage can have ameliorating impacts on metabolic disease. In contrast, aside from fasting glucose, the CREBRF variant does not associate with other features of insulin resistance such as hypertension, lipids or homeostatic model assessment of insulin resistance [1] .
In Aotearoa New Zealand, obesity and T2D are both highly prevalent in Māori and Pacific people [9] .
These conditions are also strongly associated with other prevalent metabolic-based conditions in
Māori and Pacific people, specifically gout and chronic kidney disease (CKD) [10] [11] [12] as complications of T2D and hypertension. Moreover increased BMI is causal of increased urate and risk of gout [reviewed in [13] ] and diabetic kidney disease is ascribed as the cause of renal failure in 69%
of Polynesian people [14] . CREBRF rs373863828 was not previously tested for association with gout or CKD [1] . Polynesian populations include those from West Polynesia (originating from Samoa, Tonga, Niue and Tokelau) and East Polynesia (Aotearoa New Zealand Māori and Cook Island Māori).
Given the presence of different pathogenic allele frequencies and different linkage disequilibrium structure between East and West Polynesian populations [15, 16] , understanding the genetic variation in the CREBRF gene in other Polynesian population groups besides those of Samoan and Tongan ancestry may provide novel insights into its association with increasing BMI, yet apparent reduction in risk of T2D.
In the present study, we tested the association of the CREBRF rs373863828 variant with BMI, waist circumference, T2D, gout and CKD in people of Polynesian ancestry living in Aotearoa New Zealand.
In addition, based on association of FTO genotype with variance in BMI in Europeans [17] , we tested the association of rs373863828 with variance in log-transformed BMI to detect possible underlying genetic and/or environmental influences in phenotypic variability.
Methods

Study population
Individuals, primarily from the Auckland, Waikato, and Christchurch regions of Aotearoa New
Zealand, not known to be first-degree relatives, and aged 16 years and older, were recruited as participants of the "Genetics of Gout, Diabetes and Kidney Disease in Aotearoa New Zealand" casecontrol studies [18] . Table 1 .
Whole genome Illumina Infinium CoreExome
The Illumina Infinium CoreExome v24 bead chip platform was used to genotype participants for ~500,000 variants across the whole-genome. Genotyping was performed at the University of Clustering by principal component vectors is presented in Figure S1 .
CREBRF rs373863828 genotyping
It was required to directly genotype rs373863828 because this variant was not present on the CoreExome genome-wide genotyping platform and we were unable to impute the region owing to the unavailability of Māori and Pacific reference haplotypes. A custom designed TaqMan™ probe-set (Applied Biosystems, Foster City, CA) was created for rs373863828 using a Python script plates. There was a 99% successful genotyping call rate. Genotyping of 25% of the sample set as technical replicates demonstrated 100% concordance.
Association testing
Analyses were performed using the R statistical software within RStudio v0.99.902
(https://www.rstudio.com). A multivariable linear regression model was used to test for association between the rs373863828 minor allele (c.1370A p.(457Gln)) and the continuous variables logtransformed BMI (a Box-Cox normality plot for the BMI data yielded λ=-0.39), untransformed BMI, waist circumference and serum urate), with the ß -coefficient representing the estimated effect of each copy of the rs373863828 minor allele. For binary outcomes (obesity, T2D, gout and CKD), a multivariable binomial logistic regression model was used in a similar manner, with the allelic odds ratio (OR) representing the estimated effect of each copy of the rs373863828 minor allele. Each
Polynesian population sample-set was analysed separately, and the effects combined using an inversevariance-weighted fixed effect meta-analysis. Heterogeneity between sample-sets was assessed during the meta-analysis using Cochran's heterogeneity (Q) statistic with random-effects analysis used when there was evidence for heterogeneity (P<0.05). For the BMI, waist circumference and T2D association analyses P < 0.05 was set as the significance value, given the prior probability of detecting association [1] . For the other outcomes (n=4; serum urate, gout, CKD, variance in BMI) P<0.0125
was set as the significance value to account for the multiple testing.
Models of inheritance were investigated by formulating the genotype predictor in the linear and CKD, variance in BMI) showed that power was adequate only to detect effect sizes of OR≥1.75 for gout and CKD and ≥0.032 mmol/L for serum urate ( Figure S2 ).
Testing for association of rs373863828 with variance in log-transformed BMI
Association of a genetic variant with variance in phenotype can detect a locus interacting in a nonadditive way without prior knowledge of the interacting factor (environmental, intrinsic, genetic).
Testing for association of rs373863828 with variance in log-transformed BMI was performed as previously described [25] . The variable used as a measure of variance was produced from residuals obtained from cohort-specific analyses regressing age, age 2 and age-by-sex. An independent ranked inverse normal transformation of absolute residuals generated z-scores, with squared z-scores (z 2 )
being the variance variable. To account for the influence of rs373863828 mean-effect on the variance, the mean log-transformed BMI (per genotype) was subtracted from the log-transformed BMI of each participant and the z-scores re-calculated. Linear models associating CREBRF genotype with both the unadjusted and mean-effect adjusted variance z-scores were performed (Equation 1). This analysis was also done on the rs373863828 genotype data of Minster et al [1] , with age, age 2 , age-by-sex and polity as the adjusting variables in the z-score calculation steps. The Aotearoa New Zealand sample sets along with the two sample-sets of Minster et al. [1] were combined by an inverse-variance weighted fixed-effect meta-analysis. 
Results
Prevalence of rs373863828
The allele and genotype frequencies of rs373863828 in each Polynesian sample-set are presented in Table 1 and Figure 1 . There was no evidence for deviation from Hardy Weinberg equilibrium in the various sample sets ( 
Association analysis with adiposity measures
A fixed-effect meta-analysis of the Polynesian samples showed significant association of rs373863828 with log-transformed BMI (ß=0.038, p=4.8x10 -6 ) with no evidence for heterogeneity between sample sets (P=0.19) (Tables 2 and S1; Figure 2 ). Association analysis with untransformed BMI revealed similar results (Tables 2, S2 ; Figure 2 ). One copy of the minor allele was sufficient to confer the effect ( Figure 3 ) and a sex-by-rs373863828 interaction analysis of the pooled sample-set showed no evidence of interaction with BMI (P=0.67).
A fixed effect meta-analysis showed evidence of association between rs373863828 and increased waist circumference in the full Polynesian sample-set (ß=2.98 cm per minor allele, P=1.4x10 -5 ) with no evidence for heterogeneity between sample sets (P=0.089) (Figure 2) . Adjustment of the waist circumference analysis by BMI abrogated the association with waist circumference (Table 2 ; ß lowered from 2.98 to 0.66, P=0.092).
Association analysis with T2D
A fixed-effect meta-analysis of the various sample sets revealed significant association with reduced odds of T2D (OR=0.65, P=3.4x10 -5 ) that was strengthened after adjustment by BMI (OR=0.59, P=1.9x10 -6 ) with no evidence for heterogeneity between sample sets (P=0.069) (Tables 2, S4; Figure   2 ). Similar to the observation for BMI, one copy of the minor allele appeared to be sufficient to confer the effect (Table 2: OR=0.55 for the heterozygote group compared to the major allele homozygote group). The Akaike Information Criteria analysis showed the dominant model to be similar to the additive model (0.21 less) thus the mode of inheritance for T2D was concluded to be more consistent with an additive model.
Association analysis of rs373863828 with serum urate, gout and CKD
We tested for association with serum urate (Table 2 ; Fig S3) . Unadjusted these was evidence for association of the minor A-allele with higher levels (ß=0.015 mmol/L, P=0.005, P c =0.020), however 
Association analysis of rs373863828 with variance in phenotype
The rs373863828 variant demonstrated no effect on log-transformed BMI variance at the CREBRF locus for any of the New Zealand sample-sets nor the two Samoan cohorts in the study of Minster et al. [1] . Fixed effect meta-analysis of the New Zealand (n=2282), 1990s Samoan (n=1020) and discovery Samoan (n=1876) cohorts showed no evidence of association of rs373863828 with variance in log-transformed BMI in either the unadjusted (ß=-0.053, p=0.15) or adjusted models (ß=-0.047, p=0.15) (Table S7, Figure S4 ).
Discussion
We have now confirmed the association of CREBRF variant with higher BMI ( Table 2 ), indicating that the waist circumference association was driven by overall body mass distribution rather than central adiposity.
Precisely how these genetic epidemiological findings relate to the actual CREBRF-mediated molecular pathogenesis of obesity and T2D is unclear in the absence of detailed knowledge of the molecular pathways involving CREBRF and in the absence of genetic association data with detailed body composition measures as outcome. Most population genetic variants associated with generalised obesity also associate with insulin resistance, hypertension, dyslipidemia and T2D compatible with the degree of adiposity. However, there are some genetic variants which are associated with higher BMI and percentage body fat, but lower T2D along with lower insulin resistance, hypertension, circulating triglycerides, and LDL-cholesterol. These variants are also known as 'favourable adiposity' variants [8] due to higher subcutaneous-to-visceral adipose tissue that suggests preferential fat storage away from visceral organs. The association of the minor allele of rs373863828 with a higher BMI but reduced odds of T2D is not entirely compatible with 'favourable adiposity', due to the lack of association with hypertension or lipids [1] . Consistent with the reduced odds of T2D there was weak association of the minor allele with increased insulin sensitivity by homeostatic model assessment insulin resistance in the Samoan and American Samoan populations [1] (we did not have HOMA-IR data available). Cellular bioenergetics models show that the rs373863828 minor A-allele promotes lipid and triglyceride storage at a reduced energy cost in the adipocyte suggesting that the metabolic activity of CREBRF in fat is important [1] . Detailed clinical studies are required to clarify whether visceral and subcutaneous body fat storage depots are altered among carriers of this variant.
It is notable that, from what is understood about the physiological role of CREBRF, there is no obvious role in regulation of appetite, which is seen at FTO-IRX3 and other loci regulating BMI in Europeans. However, CREBRF is widely expressed (www.gtex.org), including throughout the brain and the CREBRF gene is known to regulate the CREB3/Luman protein, which is localised to the endoplasmic reticulum and plays an important role in axonal regeneration [26] . Interestingly, the CREB3/Luman protein was identified through its association with herpes simplex virus-related host cell factor 1, which has led to the hypothesis that Luman may play a role in the viral emergence from latency [27] . It will be important to explore the relationship between CREBRF expression in the hypothalamic nuclei and the role of CREB3/Luman in the intra-axonal translation and retrograde trafficking to promote neuronal survival in response to viral stimuli and how this may relate to BMI and T2D.
Very recently a study was published reporting association of the CREBRF rs373863828 minor Aallele with higher BMI in a pooled multi-ethnic sample of 4,572 New Zealand children of Māori, Pacific, European and Asian ethnicity [28] . Given that the association analysis was pooled and population-specific association analyses were not reported we are unable to directly compare our data with that study. Furthermore, we note that the A-allele was reported at a prevalence of 0.015 in European children and 0.011 in Asian children [28] . These figures are remarkable when compared to the very low prevalences in the Genome Aggregation Database (MAF=5.3x10 -5 in East Asian, 3.3x10 
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